Mechanisms of Resistance to KRASG12C-Targeted Therapy
NS Akhave, AB Biter, DS Hong - Cancer discovery, 2021 - AACR
Although KRAS-targeted cancer therapy is revolutionary, tumors rapidly develop resistance.
Understanding the mechanisms driving this resistance and designing combination …
Understanding the mechanisms driving this resistance and designing combination …
Shared nearest neighbors approach and interactive browser for network analysis of a comprehensive non–small-cell lung cancer data set
ST Schmidt, N Akhave, RE Knightly… - JCO Clinical Cancer …, 2022 - ascopubs.org
PURPOSE Advances in biological measurement technologies are enabling large-scale
studies of patient cohorts across multiple omics platforms. Holistic analysis of these data can …
studies of patient cohorts across multiple omics platforms. Holistic analysis of these data can …
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
…, HA Araujo, G Lamberti, AJ Cooper, NS Akhave… - Cancer discovery, 2023 - AACR
In this work, we identify co-occurring genomic alterations in KEAP1 , SMARCA4 , and CDKN2A
as independent determinants of poor clinical outcomes with KRAS G12Ci monotherapy …
as independent determinants of poor clinical outcomes with KRAS G12Ci monotherapy …
Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment
Objectives Pathologists have routinely observed distinct histologic patterns of growth in early-stage
lung adenocarcinoma (LUAD), which have been suggested to be associated with …
lung adenocarcinoma (LUAD), which have been suggested to be associated with …
The next generation of KRAS targeting: Reasons for excitement and concern
NS Akhave, AB Biter, DS Hong - Molecular cancer therapeutics, 2022 - AACR
The development of selective KRAS G12C inhibitors that directly inhibit KRAS, an oncogene
historically thought to be “undruggable,” represents a watershed moment in oncology and …
historically thought to be “undruggable,” represents a watershed moment in oncology and …
[HTML][HTML] Combined Kdm6a and Trp53 deficiency drives the development of squamous cell skin cancer in mice
LK Shea, NS Akhave, LA Sutton, LA Compton… - Journal of Investigative …, 2023 - Elsevier
Cutaneous squamous cell carcinoma (cSCC) has among the highest mutation burdens of
all cancers, reflecting its pathogenic association with the mutagenic effects of UV light …
all cancers, reflecting its pathogenic association with the mutagenic effects of UV light …
Long-term Patient-Reported Outcomes in a Population-Based Cohort Following Radiotherapy vs Surgery for Oropharyngeal Cancer
…, K Diao, KA Hutcheson, NS Akhave… - … –Head & Neck …, 2023 - jamanetwork.com
Importance Oncologic outcomes are similar for patients with oropharyngeal squamous cell
carcinoma (OPSCC) treated with primary surgery or radiotherapy. However, comparative …
carcinoma (OPSCC) treated with primary surgery or radiotherapy. However, comparative …
Integrated multi-platform profiling of early-stage non-small cell lung cancer identifies relationship between disease recurrence and decreased native immune …
Introduction: Differences in the host immune environment are thought to mediate heterogeneous
treatment responses in non-small cell lung cancer (NSCLC). Unlike individual platform …
treatment responses in non-small cell lung cancer (NSCLC). Unlike individual platform …
Neoadjuvant Chemotherapy Alone or Combined with EGFR-Directed Targeted Therapy or Anti-PD-1 Immunotherapy for Locally Advanced Lacrimal Sac and …
J Goldfarb, J Fan, LG de Sousa, N Akhave… - Seminars in …, 2024 - Taylor & Francis
Background/aims We describe our findings in patients with locally advanced lacrimal sac and
nasolacrimal duct (NLD) carcinoma who received neoadjuvant systemic therapy. Methods …
nasolacrimal duct (NLD) carcinoma who received neoadjuvant systemic therapy. Methods …
Evaluation of an oncology diagnostic and screening clinic at a large safety net hospital.
…, AJ Wiele, I Cordero-Hernandez, N Akhave… - 2021 - ascopubs.org
94 Background: Increasingly, dedicated clinics have been established to expedite patients
with suspicion of malignancy into cancer care. The Lyndon B. Johnson General Hospital (…
with suspicion of malignancy into cancer care. The Lyndon B. Johnson General Hospital (…
